Atectura Breezhaler

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

下载 资料单张 (PIL)
16-10-2023
下载 产品特点 (SPC)
16-10-2023
下载 公众评估报告 (PAR)
23-06-2020

有效成分:

indacaterol acetate, Mometasone furoate

可用日期:

Novartis Europharm Limited 

ATC代码:

R03AK

INN(国际名称):

indacaterol, mometasone

治疗组:

Drugs for obstructive airway diseases,

治疗领域:

Asthma

疗效迹象:

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

產品總結:

Revision: 9

授权状态:

Authorised

授权日期:

2020-05-30

资料单张

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 16-10-2023
产品特点 产品特点 保加利亚文 16-10-2023
公众评估报告 公众评估报告 保加利亚文 23-06-2020
资料单张 资料单张 西班牙文 16-10-2023
产品特点 产品特点 西班牙文 16-10-2023
公众评估报告 公众评估报告 西班牙文 23-06-2020
资料单张 资料单张 捷克文 16-10-2023
产品特点 产品特点 捷克文 16-10-2023
公众评估报告 公众评估报告 捷克文 23-06-2020
资料单张 资料单张 丹麦文 16-10-2023
产品特点 产品特点 丹麦文 16-10-2023
公众评估报告 公众评估报告 丹麦文 23-06-2020
资料单张 资料单张 德文 16-10-2023
产品特点 产品特点 德文 16-10-2023
公众评估报告 公众评估报告 德文 23-06-2020
资料单张 资料单张 爱沙尼亚文 16-10-2023
产品特点 产品特点 爱沙尼亚文 16-10-2023
公众评估报告 公众评估报告 爱沙尼亚文 23-06-2020
资料单张 资料单张 希腊文 16-10-2023
产品特点 产品特点 希腊文 16-10-2023
公众评估报告 公众评估报告 希腊文 23-06-2020
资料单张 资料单张 法文 16-10-2023
产品特点 产品特点 法文 16-10-2023
公众评估报告 公众评估报告 法文 23-06-2020
资料单张 资料单张 意大利文 16-10-2023
产品特点 产品特点 意大利文 16-10-2023
公众评估报告 公众评估报告 意大利文 23-06-2020
资料单张 资料单张 拉脱维亚文 16-10-2023
产品特点 产品特点 拉脱维亚文 16-10-2023
公众评估报告 公众评估报告 拉脱维亚文 23-06-2020
资料单张 资料单张 立陶宛文 16-10-2023
产品特点 产品特点 立陶宛文 16-10-2023
公众评估报告 公众评估报告 立陶宛文 23-06-2020
资料单张 资料单张 匈牙利文 16-10-2023
产品特点 产品特点 匈牙利文 16-10-2023
公众评估报告 公众评估报告 匈牙利文 23-06-2020
资料单张 资料单张 马耳他文 16-10-2023
产品特点 产品特点 马耳他文 16-10-2023
公众评估报告 公众评估报告 马耳他文 23-06-2020
资料单张 资料单张 荷兰文 16-10-2023
产品特点 产品特点 荷兰文 16-10-2023
公众评估报告 公众评估报告 荷兰文 23-06-2020
资料单张 资料单张 波兰文 16-10-2023
产品特点 产品特点 波兰文 16-10-2023
公众评估报告 公众评估报告 波兰文 23-06-2020
资料单张 资料单张 葡萄牙文 16-10-2023
产品特点 产品特点 葡萄牙文 16-10-2023
公众评估报告 公众评估报告 葡萄牙文 23-06-2020
资料单张 资料单张 罗马尼亚文 16-10-2023
产品特点 产品特点 罗马尼亚文 16-10-2023
公众评估报告 公众评估报告 罗马尼亚文 23-06-2020
资料单张 资料单张 斯洛伐克文 16-10-2023
产品特点 产品特点 斯洛伐克文 16-10-2023
公众评估报告 公众评估报告 斯洛伐克文 23-06-2020
资料单张 资料单张 斯洛文尼亚文 16-10-2023
产品特点 产品特点 斯洛文尼亚文 16-10-2023
公众评估报告 公众评估报告 斯洛文尼亚文 23-06-2020
资料单张 资料单张 芬兰文 16-10-2023
产品特点 产品特点 芬兰文 16-10-2023
公众评估报告 公众评估报告 芬兰文 23-06-2020
资料单张 资料单张 瑞典文 16-10-2023
产品特点 产品特点 瑞典文 16-10-2023
公众评估报告 公众评估报告 瑞典文 23-06-2020
资料单张 资料单张 挪威文 16-10-2023
产品特点 产品特点 挪威文 16-10-2023
资料单张 资料单张 冰岛文 16-10-2023
产品特点 产品特点 冰岛文 16-10-2023
资料单张 资料单张 克罗地亚文 16-10-2023
产品特点 产品特点 克罗地亚文 16-10-2023
公众评估报告 公众评估报告 克罗地亚文 23-06-2020